1 billion life sciences fund to place another round of big bets. The company has four businesses focused on addressing specific gaps in treatment and care to make an impact across Bain Capital Life Sciences was the lead investor in a private financing that helped to recapitalize Dicerna in 2017 and continues to be an active participant in the Company’s success through its representation on the Board of Directors. We want to support you in this journey by providing you with a Bain leader as a mentor and a sounding board. Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells. 9. Morgan in their healthcare investment banking group, advising biotechnology and pharmaceutical clients on a range of strategic alternatives including M&A and debt/equity financings. C5a is a powerful inflammatory mediator involved Jeffrey Schwartz joined Bain Capital in 2004 and is a Partner of Bain Capital Life Sciences. Arcutis Biotherapeutics (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. Chris Gordon is a Managing Director at Bain Capital. Imperative Care is a commercial-stage medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. 1 billion in 2021). & NEW YORK--(BUSINESS WIRE)--EQRx, Inc. A list of eligible schools can be found in the FAQs section below. Feb 8, 2024 · Bain Capital Life Sciences Investments. ExperienceBain is a pre-MBA program designed for candidates who've been accepted into an MBA program at an eligible school starting Fall 2024. , developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital Life Sciences. Founded in 2010, Axtria helps Life Sciences companies transform the product commercialization journey to drive sales growth and improve healthcare outcomes for patients. Ambassador to Ireland and as an associate InflaRx (Nasdaq: IFRX) is a biotechnology company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. Previously, he focused on Energy in the Industrial & Energy Vertical and spent time in the Technology, Media Aug 17, 2021 · Published: Aug 17, 2021 By Vanessa Doctor, RN. Prior to Biogen, Dr. Amunix Pharmaceuticals, based in South San Francisco, CA, is focused on developing masked T cell engagers and cytokines to bring the promise of these potent immune-activating biotherapeutics to patients with solid tumor cancers. Apply during the summer to start in the fall. F. The fund has investment ranging from USD 25 million to USD 100 million. You are eligible for this program if you’re interested in one of our Europe, Middle East, Africa Managing Director, Bain Capital. Head of Human Resources, Double Impact, Life Sciences, Tech Opportunities & Real Estate Experience: Bain Capital · Location: Boston · 500+ connections on LinkedIn. Existing investors Perceptive Advisors, Janus Capital Management and Biogen also participated in the round. The Bain Capital square symbol is a trademark of Bain Capital, LP. Hybrid work in Boston, MA 02110. As the pioneer of FFRCT, which is now supported by the ACC/AHA Chest Pain Guidelines, HeartFlow continues to advance the diagnosis and management of CAD. Hack served as Chief Financial Officer of Editas Medicine, Inc. From 2015 to 2019, he was Chief Financial Officer of Editas Medicine (Nasdaq: EDIT) where he had responsibility for finance, investor relations, business development, information technology, and operations. May 23, 2017 · Private equity firm Bain Capital LP said on Tuesday it had raised $720 million for its first investment fund focused exclusively on the life sciences sector. P. Nov 22, 2016 · Bain Capital is looking to raise an undisclosed amount of money for an investment fund focused on life sciences companies, according to a regulatory filing on Tuesday. Affera is developing a comprehensive integrated platform to efficiently deliver durable therapy for a broad set of cardiac arrhythmia patients. com Lead to Inspire fellowship. If you already have your school email, please register with it. $150,000 - $175,000 a year. Diagnostics and lab services show the progress in the “democratization” of CAMBRIDGE, Mass. From 2014 to 2016, Dr. The Company’s lead asset is PLB1001 (Vebreltinib), a small-molecule inhibitor that targets MET tyrosine kinase activity. If you agree to our use of cookies, please continue to use our site. Their latest investment was in Century Therapeutics as part of their PIPE on April 11, 2024. Daisak joined Bain Capital Life Sciences in 2021. Bain Capital Life Sciences Investors's largest holding is NewAmsterdam Pharma Company NV with shares held of 10,473,913. RNA startup ADARx raises $200M from Bain, TCGX to bring RNAi 'to the next level'. Prior to joining Bain Capital, Mr. Deftos joined Bain Capital in 2012. View Lindsay Wong’s profile on LinkedIn, a professional community of 1 billion members. Danforth served with the U. , Ph. (NASDAQ: CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today © 2012-2024 Bain Capital, LP. Bain Capital, LPis one of the world’s leading private investment firms with approximately $185 billion of assets under management that creates lasting impact for our investors, teams, businesses, and the communities in which we live. We provide the confidence made possible when reliability meets innovation, helping our clients run Apr 10, 2023 · The life sciences tools sector saw 21 deals (compared with 34 in 2021), and disclosed deal value was $8. 83%. Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. She is an Associate. , is Managing Director of Bain Capital Life Sciences. Oct 16, 2020 · BOSTON, MA, October 16, 2020 – Bain Capital Real Estate, the real estate investing business of Bain Capital, and Phase 3 Real Estate Partners, Inc. Apr 6, 2023 · HeartFlow, Leader in Revolutionizing Precision Heart Care, Closes $215 Million in Series F Funding Led by Bain Capital Life Sciences Oct 22, 2020 · Since 1984, Bain Capital has developed global reach, deep expertise and a proven track record in life sciences industries across its Private Equity, Credit, Public Equity, Venture and Real Estate Web Fraud and Phishing Warning. Field advised healthcare and private equity clients across a range of different strategic and operational problems. ADARx has a growing pipeline of RNA therapeutics for treating diseases across Settings. The company is leveraging its proprietary XPAT® and XPAC™ platforms to advance a pipeline of novel drugs that are © 2012-2024 Bain Capital, LP. This site uses cookies. BOSTON-- (BUSINESS WIRE)-- Bain Capital Specialty Finance, Inc. Ricky Lijing Sun, PhD. Prior to joining Bain Capital Life Sciences, Mr. EXPERIENCE. All Rights Reserved. The sector traditionally has attracted mostly corporate buyers, but expanding treatment and detection of infectious diseases has allowed more private equity investors to get their foot in the door. Click here to read more about the breadth and legacy of our efforts. ADARx Pharmaceuticals, located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. Your expertise, eagerness to learn, and problem-solving abilities will drive change for our clients from day one—but you won’t do it alone. Scroll down to Investments Principal @ Bain Capital Life Sciences · Over the past 16 years, I have been a full time clinician and have grown a robust clinical trial program at NJRetina. While the biotech funding slowdown is still a hurdle, investors began displaying more comfort putting money to work in early-stage therapies and precommercial medical devices. Koppel, M. We’ll post when new ones are available. S. Field was a management consultant at Bain & Company in New York. Before attending law school, Ms. He is a Managing Director on the Bain Capital Life Sciences team. But this human-centric mindset doesn’t just exist externally Continue. Roughly 410 were “unique” deals, and roughly 50 deals were multifund. Easily apply. 27 Investments. We are building a portfolio of innovative, first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic Settings. Oct 22, 2020 · CAMBRIDGE, MA, October 22, 2020 – A premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences (“Bain Capital”), and RA Capital Management (“RA Capital”) (collectively the “Investor Group”) together with Sarepta Therapeutics, Inc. Life Sciences. Ms. Media may contact baincapital@stantonprm. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that She is the General Counsel for Life Sciences. See full list on bain. Get the right Associate life sciences venture capital job with company ratings & salaries. Their cloud-based platforms - Axtria DataMAx CAMBRIDGE, Mass. Experience. Department of State as special assistant to the U. 1 billion. He currently leads Bain Capital’s North American healthcare team and is a member of the investment committee for the Bain Capital Life Sciences Fund. Bain Capital Life Sciences seeks to build a diverse portfolio of high-impact, high-value-creating companies by adhering to our Guiding Principles in our rigorous, science-first diligence. (“Sarepta”) (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today announced a Mr. Aug 26, 2020 · Freenome CEO Gabriel Otte stated, “We are delighted to have Bain Capital Life Sciences and Perceptive Advisors as lead investors, and thank all of our new and existing investors for their Jun 17, 2020 · Bai also worked at the Boston Consulting Group and Bain Capital Private Equity, focusing on healthcare and life science investing, operations, and strategies. In total, around 200 private equity firms participated in at least one life sciences deal, and around 170 of Jun 13, 2019 · Bain Capital has raised a $1. Bain Capital also oversees one of the largest private healthcare IT portfolios in the US. Posted 13 days ago ·. The Company’s approach relies on technology that was developed at Johns Hopkins University in the labs of Ellen Bredenkoetter, Incoming Bain Consultant, Sloan School of Management. Management will host a conference call on Tuesday, May 7, 2024 at 8:00 a. Adam M. (NASDAQ: CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Zamani joined Bain Capital in 2018. Feb 8, 2024 · Company Description. Field joined Bain Capital in 2020. m. Danforth was a corporate attorney at Ropes & Gray, LLP in Boston, primarily focused on private equity. Eastern Time to discuss the Company Our awardees contribute significantly to the advancement of life science and biomedical research. Kestra was founded in 2014 by leaders from the external (AED) and internal (ICD) defibrillation industries. FIS is a leading global provider of financial services technology solutions for financial institutions, businesses and developers. The firm seeks to invest in companies operating in the pharmaceutical, biotechnology, medical device, diagnostic, and life science sectors. 9 billion to fund future projects that involve medical, drug, and biotechnology projects. Full-time. Bain Capital Life Sciences Fund III is a private equity growth expansion fund co-managed by Bain Capital and Bain Capital Life Sciences. Sun joined Bain Capital in 2016. Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. Downing was a resident physician at the Brigham and Women’s Hospital in Boston, where he cared for patients on the inpatient medical service and in the outpatient clinic. Funds affiliated with Bain Capital Private Equity and Bain Capital Life Sciences have committed $350 million with the ability to provide additional capital should it be needed in the future. Carve-outs of large, mature assets as well as small, innovative growth stories drew investors’ interest. Koppel was EVP of Corporate Development and Chief Strategy Officer at Biogen. We improve the digital transformation of our financial economy, advancing the way the world pays, banks and invests. 2014. Weber joined Bain Capital Life Sciences in 2017. Oct 27, 2021 · In conjunction with Bain Capital’s investment, Koppel and Nicholas Downing, MD, a Principal at Bain Capital Life Sciences, will join the Cardurion Board of Directors. Avistone Pharmaceuticals is an oncology company focused on developing innovative therapies for patients with significant unmet medical needs globally. Axtria is a global provider of cloud software and data analytics to the Life Sciences industry. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal Settings. (NASDAQ: EDIT), from July 2015 to March 2019. Dr. Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. You are at the beginning of your MBA journey and will soon have to consider the next steps in your career. Boston. Private investment firm Bain set up its first life science fund in 2016, pulling in $600 million Advanced degree holders (JDs, MDs, and PhDs) bring unique and valuable perspectives to our casework. Daisak worked at J. SpringWorks Therapeutics is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. Jennie Daisak. Zamani was a Partner at McKinsey & Company, where he was a leader in the Biopharmaceutical and Medical Products Practice. The life sciences arm of Boston-based private equity firm Bain Capital has successfully raised $1. Weekend—Open for women with 3-8 years of work experience. Bain Capital Life Sciences has made 27 investments. For additional information, please contact lifesciences@baincapital. IT services is a very people-driven business and our ability to partner with Jan 31, 2023 · We expect pharma M&A activity to rebound quickly as companies look to fill the potential growth gap from the $100 billion in patents set to expire by 2030. He initially joined Bain Capital Public Equity in 2003, where he was a leader within the healthcare sector until 2014. Cozean joined Bain Capital in 2013. Affera is a medical technology company dedicated to delivering unrivaled innovative solutions to address the rapidly growing demands for cardiac arrhythmia treatment. Deals in life sciences tools deals nearly doubled to 34 in 2021, while disclosed deal value soared to a record $11. ALUMNI VENTURES. Bain Capital Life Sciences & Bain Capital Private Equity. Prior to his current role, he was a member of Bain Capital’s Private Equity team, where he focused on healthcare investments. The company is tackling diseases by combining its deep expertise in neurocircuitry with a focus on targeted receptor subtype selectivity and a differentiated approach to pharmacology. I have been the principal Adam M. Life sciences or biotech background strongly preferred. Mr. The company’s proprietary technology platform, called MAPS™, enables the high affinity binding of protective polysaccharides and proteins in a single Kestra Medical Technologies is a privately held wearable medical device and digital healthcare company that protects cardiac patients with diagnostic monitoring and therapeutic technologies that are intuitive, intelligent, and mobile. Before McKinsey, he was a resident in Plastic Surgery at the University of We are thrilled by the support of Bain Capital Life Sciences and Perceptive Xontogeny Venture Fund to continue the clinical and regulatory… This site uses cookies. At Bain & Co, Mr. 95 open jobs for Associate life sciences venture capital. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large Settings. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. 1-5 years of venture capital experience, supplemented by 7-10 years of overall work experience. Koppel rejoined Bain Capital in 2016 as a Partner of Bain Capital Life Sciences. Series C financing led by Bain Capital Life Sciences to support PKU program and pipeline in immune-mediated diseases and cancer; Ron Renaud joins Jnana's Board of DirectorsJnana initiates Phase 1 clinical trial of JNT-517, a potential first-in-class oral Feb 5, 2020 · IRVINE, California-JenaValve Technology, Inc. Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. To see how cookies are used, please review our cookie notice. Affinivax is focused on the most challenging bacterial infections, both improving upon existing vaccines and providing vaccines for which there are no prevention strategies available today. Prior to joining Bain Capital, Ms. ADARx has developed proprietary RNA delivery platforms and technology for silencing or editing target mRNA. She is a Partner and Head of Human Resources for Life Sciences, Double Impact, Tech Opportunities and Real Estate businesses. X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system. Fellowship—Open to first year MBA students. Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases. Cerevel will seek to expand treatment options in a therapeutic area where there is an urgent unmet need for patients. com. , today announced the sale of Genesis South San Francisco, a Class A life sciences portfolio located at the entrance to the South San Francisco life science cluster, one of the largest life science clusters in the world. , a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III, Inc. Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Prior to joining the Life Sciences team, he was a member of the North American Private Equity team in the Healthcare Vertical. This article is part of Bain's 2023 M&A Report. We measure our success through the achievements of our alumni who have careers in academia, industry, science communication and policy development, scientific foundations, patent law, biotech venture capital groups, consulting and science publishing. He is a Vice President on the Bain Capital Life Sciences team. (NYSE: BCSF, the “Company”) today announced it will report its financial results for the first quarter ended March 31, 2024 on Monday, May 6, 2024 after market close. Search Associate life sciences venture capital jobs. Their last reported 13F filing for Q1 2024 included $1,244,287,799 in managed 13F securities and a top 10 holdings concentration of 81. Dec 20, 2021 · Description. Bain Capital Life Sciences Investors is based out of Boston. Bain Capital Healthcare We have HeartFlow is transforming precision coronary care with the only AI-powered non-invasive integrated heart care solution across the CCTA pathway. HeartFlow’s suite of non-invasive technologies Settings. Avistone has an extensive portfolio and pipeline of targeted therapies. The differentiated skillset Mr. Jun 17, 2020 · Bai also worked at the Boston Consulting Group and Bain Capital Private Equity, focusing on healthcare and life science investing, operations, and strategies. Bain Capital is one of the most active private equity investors globally in healthcare, backing many of the largest healthcare services, technology and life sciences operators. Investors. About Cardurion Pharmaceuticals Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation Mar 15, 2022 · At a Glance. He is a Partner on the Bain Capital Life Sciences team. and other top-tier healthcare investors Upon . Prior to joining Bain Capital, Dr. Downing joined Bain Capital in 2018. Lead to inspire webinars—Open to everyone who is interested. The initiative was spearheaded by the 16-person team at Bain Capital Life Sciences with the goal to find and Thrive is a private company based in Cambridge, MA and Baltimore, MD that is focused on developing a blood-based, multi-cancer screening test called CancerSEEK to screen for cancer in adults older than 50 with no known cancer diagnosis. Settings. D. He is a Principal. Jan 3, 2024 · At a Glance Although the life sciences sector continues to attract buyout activity, private equity deal value in 2023 struggled to match the levels of 2022. 2 billion (compared with $11. Case Study. Jul 30, 2020 · In the news Cerevel Therapeutics and Arya Sciences Acquisition Corp II Announce Business Combination, Creating a Publicly Listed Leader in Neuroscience Drug Development Leading institutional investors commit $320 million through a common stock private investment in public equity (“PIPE”) led by Bain Capital, Perceptive Advisors, Pfizer Inc. Hack joined Bain Capital in 2019 and is a Partner with Bain Capital Life Sciences. Hack is a Managing Director at Bain Capital Life Sciences, a private equity fund that invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Weber worked at J. Our lead clinical candidate is mavorixafor, a selective, small-molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy across a variety of EyeBio doubled the size of its original Series A raise in November 2023 with new investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC. Apply in February or March to attend in person in Milan in May. 23. Aug 16, 2021 · 8. Kestra, a wearable medical device and digital healthcare company, has a mission that is inherently people-driven: to protect patients with technologies that are intuitive, intelligent, and mobile. OGSIVEO™ (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid 🌟 The Bain Capital Life Sciences Fellowship representative are hosting an… 🔬 Calling all PhD and MD candidates passionate about life sciences! Liked by Danielle LeMott, PHR EXPERIENCE. Bain Capital Healthcare We have built one of the largest and deepest healthcare investing teams in the world. You’ll join a collaborative and supportive network of digital innovators to deliver extraordinary Andrew A. Founded in 2016, Bain Capital Life Sciences is the corporate venture capital arm of Bain Capital, based in Boston, Massachusetts. The equity and debt markets will inevitably stabilize, and the top 25 pharma, medtech, and payer companies all have cash on hand. Mar 30, 2017 · The round was led by RA Capital Management and Bain Capital Life Sciences, together with funds from RTW Investments, Foresite Capital, Cormorant Asset Management LLC, entities affiliated with Leerink Partners, and an unnamed healthcare fund. Apr 10, 2023 · There were roughly 460 PE transactions for US- and European-based biopharma and life sciences tools assets between 2017 and the end of the first half of 2022. Morgan in their healthcare investment banking group, assisting both large and small pharma/biotech clients across several transaction teams, including buy-side and sell-side M&A, equity, and debt financings. Sun served as a Vice President at BlackRock, as a member of the Fundamental Equity division Settings. The fund is located in Boston, Massachusetts. Cardurion was founded by physician-scientists with world-class expertise in cardiovascular signaling pathways, and a shared passion to find Sep 30, 2021 · Bain Capital Life Sciences invests in pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies across the globe, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs. He joined the firm in 1997 and has significant experience in private equity investing, with a specialized focus in the healthcare sector. Prior to joining Bain Capital, from 2013 to 2016, he was a Director of Corporate Development and Strategy at Biogen. The company is using its proprietary geographically precise solutions Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform. He initially joined Bain Capital in 2003 as a member of the Public Equity team where he worked as a leader within the healthcare sector until 2014. The fund targets investments in the life science sector. Otis St & Summer St. uh xi hg to pb dj ec pa wr dy